DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance

Annals of Hematology

Volumn 89, Issue 2, 2010, Pages 191-199

  Stanganelli, Carmen ^a   Arbelbide, Jorge ^b   Fantl, Dorotea Beatriz ^b   Corrado, Claudia ^a   Slavutsky, Irma ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

DNA methylation; MGUS; Multiple myeloma; Tumor suppressor genes

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA; IMMUNOGLOBULIN G; PROTEIN P73; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SUPPRESSOR OF CYTOKINE SIGNALING 1; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; DNA BINDING PROTEIN; NUCLEAR PROTEIN; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; DNA SEQUENCE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE; TUMOR SUPPRESSOR GENE; GENETICS; MIDDLE AGED; PHYSIOLOGY;

ADP-RIBOSYLATION FACTORS; ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NUCLEAR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 74049122570     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0818-3     Document Type: Article

References (50)

1. Ahuja N, Li Q, Nohan AL, Baylin SB, Issa JP (1998) Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 58:5489-5494.
2. Bird A (1986) CpG-rich islands and the function of DNA methylation. Nature 321:209-213.
3. Boultwood J, Wainscoat JS (2007) Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 138:3-11.
4. Chim CS, Liang R, Fung TK, Choi CL, Kwong YL (2005) Infrequent epigenetic dysregulation of CIP/KIP family of cyclindependent kinase inhibitors in multiple myeloma. Leukemia 19:2352-2353.
5. Chim CS, Liang R, Fung TK, Choi CL, Kwong YL (2007) Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol 60:664-669.
6. Chim CS, Liang R, Leung MH, Kwong YL (2007) Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J Clin Pathol 60:104-106.
7. Costello JF, Fruhwald MD, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki D, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138.
8. Depil S, Saudemont A, Quesnel B (2003) SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. Leukemia 17:1678-1679.
9. Durie BG, Salmon E (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842-854.
10. Esteller M, Tortola S, Toyota M, Capella G, Peinado M, Baylin S (2000) Hypermethylation-associated inactivation of p14ARF is independent of p16INK4a methylation and p53 mutational status. Cancer Res 60:129-133.
11. Esteller M (2003) Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 109:80-88.
12. Feinberg AP (2004) The epigenetics of cancer etiology. Semin Cancer Biol 14:427-432.
13. Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4:143-153.
14. Gallagher S, Kefford F, Rizos H (2006) The ARF tumor suppressor. Int J Biochem Cell Biol 38:1637-1641.
15. Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG, Oseika R (2004) DNA methylation changes in multiple myeloma. Leukemia 18:1687-1692.
16. Galm O, Herman J, Baylin S (2006) The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 20:1-13.
17. Gonzalez-Paz N, Chung WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R (2007) Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 109:1228-1232.
18. Greipp P, San Miguel J, Durie BG, Crowley J, Barlogie B, Bladé J, Boccadoro M, Child A, Avert-Loiseau H, Kyle R, Lahuerta J, Ludwing H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412-3420.
19. Guillerm G, Gyan E, Wolowiec D, Facon T, Avet-Loiseau H, Kuliczkowski K (2001) p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 98:244-246.
20. INK4a gene methylation in multiple myeloma. Haematologica 88:476-478.
21. Herman J, Graff J, Myohanen S, Nelkin B, Baylin S (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826.
22. Herman J, Baylin S (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054.
23. Hideshima T, Bergsagel PL, Kuehl W, Anderson K (2004) Advances in biology of multiple myeloma: clinical applications. Blood 104:607-618.
24. Jones P, Baylin S (2007) The epigenomics of cancer. Cell 128:683-692.
25. Klein B, Zhang XG, Lu ZY, Bataille R (1995) Interleukin-6 in human multiple myeloma. Blood 85:863-872.
26. Krämer A, Schultheis B, Bergmann J, Willer A, Hegenbart U, Ho AD, Goldschmidt H, Hehlmann R (2002) Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia 16:1844-1851.
27. Kreb D, Hilton D (2000) SOCS: physiological suppressor of cytokine signaling. J Cell Science 113:2813-1819.
28. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J, Issa J (2007) Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 13:3796-3802.
29. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860-1873.
30. Kyle R, Therneau T, Rajkumar V, Larson D, Plevak M, Oxford J, Dispenzieri A, Katzmann J, Melton J (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 345:1362-1369.
31. Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA (1999) Comparison of IL-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 93:303-305.
32. Le MH, Yang HY (2003) Regulators of G1 cyclin-dependent kinases and cancer. Cancer Metast Rev 22:435-449.
33. Martin P, Garcia-Cosio M, Santon A, Bellas C (2008) Aberrant gene promoter methylation in plasma cell dyscrasias. Exp Mol Pathol 84:256-261.
34. Mateos MV, García-Sanz R, Lopez-Perez R, Balanzategui A, González MI, Fernández-Calvo J, Moro MJ, Hernandez J, Caballero MD, González M, San Miguel JF (2001) P16/INK4A gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. The Hematology J 2:146-149.
35. Mateos MV, Garcia-Sanz R, Lopez-Perez R, Moro MJ, Ocio E, Hernandez J, Megido M, Caballero MD, Fernández-Calvo J, Bárez A, Almeida J, Orfão A, González M, San Miguel JF (2002) Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 118:1034-1040.
36. Moll U, Slade N (2004) p63 and p73: roles in development and tumor formation. Mol Cancer Res 2:371-386.
37. Nakatsuka S, Liu A, Yao M, Takakuwa T, Tomita Y, Hoshida Y, Nishiu M, Aozasa K (2003) Methylation of promoter region in p27 gene plays a role in the development of lymphoid malignancies. Int J Oncol 22:561-568.
38. Ng MH, Chung YF, Lo KW, Wickham NKW, Lee JCK, Huand DP (1997) Hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89:2500-2506.
39. Ogata A, Anderson KC (1996) Therapeutic strategies for inhibition of interleukine-6 mediated multiple myeloma cell growth. Leuk Res 20:303-307.
40. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative ready frames of the INK4a tumor suppressor gene encodes two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
41. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, Mueller M, Krammer PH, Melino G, Candi E (2005) p73 induces apoptosis by different mechanims. Biochem Bioph Res Comm 331:713-717.
42. Reddy J, Shivapurkar N, Takahashi T, Parikh G, Stastny V, Echebiri C, Crumrine K, Zöchbauer-Müller S, Drach J, Zheng Y, Feng Z, Kroft SH, McKenna RW, Gazdar AF (2005) Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 24:732-736.
43. San Miguel J, Garcia-Sanz R, Lopez-Perez R (2005) Analysis of methylation pattern in multiple myeloma. Acta Haematol 114 (Suppl 1):23-26.
44. Seidl S, Ackermann J, Kaufmann H, Keck A, Nosslinger T, Zielinski CC, Drach J, Zochbauer-Mullerancer S (2004) DNAmethylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 15:2598-2606.
45. Shivakumar L, Minna J, Sakamaki T, Pestell R, White M (2002) The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 22:4309-4318.
46. Takahashi T, Shivapurkar N, Reddy J, Shigematsu H, Miyajima K, Suzuki M, Toyooka S, Zöchbauer-Müller S, Drach J, Parikh G, Zheng Y, Feng Z, Kroft SH, Timmons C, McKenna RW, Gazdar AF (2004) DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res 10:2928-2935.
47. Uchida T, Kinoshita T, Ohno T, Nagai H, Saito H (2001) Hypermethylation of p16INK4a gene promoter during the progression of plasma cell dyscrasia. Leukemia 15:157-165.
48. Vidal A, Koff A (2000) Cell-cycle inhibitors: three families united by a common cause. Gene 247:1-15.
49. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ (2000) Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 275:35669-35672.
50. Wong IHN, Ng MLH, Huang DO, Lee JC (2000) Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 95:1942-1949.